迈瑞医疗(300760):25Q1环比向上,业绩年内或逐步复苏
Guotou Securities· 2025-05-05 14:32
Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 263.83 CNY [4][10]. Core Views - The company reported a revenue of 36.726 billion CNY in 2024, a year-on-year increase of 5.14%, and a net profit of 11.668 billion CNY, up 0.74% year-on-year [1]. - The first quarter of 2025 showed a revenue of 8.237 billion CNY, a year-on-year decrease of 12.12%, but a quarter-on-quarter increase of 13.76% [1]. - The recovery in bidding activities since the end of 2024 is expected to gradually improve the company's performance [2]. - The company is positioned as a leader in industry digitization, leveraging AI to enhance business expansion and innovate its business model [4][9]. Financial Performance Summary - In 2024, the company's revenue from life information and support business was 13.557 billion CNY, a decrease of 11.11%, while the minimally invasive surgery segment grew over 30% [3]. - The in-vitro diagnostics business generated 13.765 billion CNY in 2024, marking a year-on-year growth of 10.82% [3]. - The medical imaging business achieved a revenue of 7.498 billion CNY in 2024, with a growth of 6.60% year-on-year [3]. - The company expects revenue growth rates of 10.5%, 15.5%, and 14.6% for 2025 to 2027, respectively, with net profit growth rates of 9.7%, 15.3%, and 15.0% [10].
银轮股份(002126):2025年Q1营收、利润同比稳步增长,第三曲线业务快速开拓
Guohai Securities· 2025-05-05 14:31
研究所: 证券分析师: 戴畅 S0350523120004 daic@ghzq.com.cn 证券分析师: 吴铭杰 S0350524090003 wumj@ghzq.com.cn [Table_Title] 2025 年 Q1 营收&利润同比稳步增长,第三曲线 业务快速开拓 2025 年 05 月 05 日 公司研究 评级:买入(维持) ——银轮股份(002126)2025 年 Q1 季报点评 《银轮股份(002126)2024 年年报点评:2024 年 Q4 利润环比增速受减值拖累,2024 全年新增订单 充沛(买入)*汽车零部件*戴畅,吴铭杰》—— 2025-04-22 《银轮股份(002126)2024 年 Q3 季报点评:2024 年 Q3 归母净利润同比提升,热交换业务未来成长 空间广阔(买入)*汽车零部件*戴畅,吴铭杰》— —2024-10-30 国海证券研究所 请务必阅读正文后免责条款部分 相关报告 事件: 2025 年 4 月 29 日,银轮股份发布 2025 年 Q1 季报:2025 年 Q1 实现 营收 34.16 亿元,同比+15.05%;实现归母净利润 2.12 亿元,同比 +10.8 ...
浦发银行(600000):2025一季报点评:营收增速回正,资产质量改善
Huafu Securities· 2025-05-05 14:30
华福证券 股份制银行Ⅲ 2025 年 05 月 05 日 公 司 研 究 浦发银行(600000.SH) 2025 一季报点评—营收增速回正,资产质量改善 投资要点: 营收增速回正 公 司 财 报 点 评 浦发银行 2025Q1 营收增速回正,利润继续正增长。公司 2025 一 季度营收增速为 1.3%,环比 2024 全年提升 2.9pct;公司 2025Q1 利润 增速为 1.02%,增速较 2024 全年回落,原因主要是公司加大拨备计提 力度、夯实资产质量,拨备对利润的贡献边际减少。同业对比来看, 浦发银行一季度营收和归母净利润同比增速均在股份行中排名第 2,业 绩增长能力优于可比同业。 浦发银行营收回正的主要驱动因素来自利息净收入增速转正,同 时非息业务正贡献营收。公司 2025Q1 利息净收入同比增长 0.48%,增 速较 2024 全年提升 3.62pct,利息净收入正增长一方面来自规模贡献, 另一方面来自净息差的负向拉动作用减轻。非息方面,浦发银行 2025Q1 非息业务走势明显优于可比同业,公司 2025Q1 手续费和佣金 收入、其他非息收入分别同比增长-0.03%、4.47%,增速较 202 ...
鱼跃医疗(002223):2025Q1超预期,看好公司产品力提升和出海加速
Shenwan Hongyuan Securities· 2025-05-05 14:27
上 市 公 司 2025 年 05 月 05 日 鱼跃医疗 (002223) ——2025Q1 超预期,看好公司产品力提升和出海加速 | | 2025 年 03 月 31 日 | 17 6、 | | --- | --- | --- | | (元) | 13.07 | 现 | | 6 | 19.43 | 数 | | A 股 (百万) 股(百万) | 1,002/940 | 收 | 报告原因:有业绩公布需要点评 买入(维持) | 市场数据: | 2025 年 04 月 30 日 | | --- | --- | | 收盘价(元) | 34.46 | | 一年内最高/最低(元) | 42.08/30.05 | | 市净率 | 2.6 | | 股息率%(分红/股价) | 3.48 | | 流通 A 股市值(百万元) | 32,398 | | 上证指数/深证成指 | 3,279.03/9,899.82 | | 注:"股息率"以最近一年已公布分红计算 | | | 基础数据: | 2025 年 03 月 31 日 | | --- | --- | | 每股净资产(元) | 13.07 | | 资产负债率% | 19.43 | ...
豆神教育(300010):2024年&2025Q1业绩点评:盈利能力持续提升,关注AI直播课上线节奏
Guohai Securities· 2025-05-05 14:25
Investment Rating - The report assigns an "Accumulate" rating for the company, marking its first coverage [2][10][11]. Core Insights - The company reported a revenue of 760 million yuan for 2024, a year-on-year decrease of 23.8%, while the net profit attributable to shareholders reached 140 million yuan, showing a significant increase of 334% year-on-year [2]. - In Q1 2025, the company achieved a revenue of 190 million yuan, a slight decline of 0.6% year-on-year, with a net profit of 37.37 million yuan, reflecting a growth of 68.1% year-on-year [3]. - The improvement in profitability is attributed to a 46.2% decrease in procurement costs for software, hardware, and services, leading to a 14.2 percentage point increase in overall gross margin [2][10]. Financial Performance Summary - For 2024, the company’s gross margin improved to 46%, with a net profit margin of 18.1%, up by 14.9 percentage points year-on-year [2][11]. - The company’s operating expenses as a percentage of revenue were 29.8% for sales, 12.7% for management, and a reduction in R&D expenses due to increased capitalized expenditures [2]. - The forecast for 2025-2027 indicates expected revenues of 960 million yuan, 1.185 billion yuan, and 1.387 billion yuan, respectively, with net profits projected at 203 million yuan, 293 million yuan, and 372 million yuan [9][10][11]. AI Integration and Product Development - The company has integrated AI into its curriculum, generating revenue of 27.31 million yuan from AI education services in 2024 [4]. - The AI live classes have shown positive feedback during internal testing, enhancing the classroom experience with real-time interaction and monitoring of student engagement [4][8]. Market Performance - As of April 30, 2025, the company's stock price was 7.15 yuan, with a market capitalization of approximately 14.78 billion yuan [6][11]. - Over the past 12 months, the company's stock has outperformed the CSI 300 index, with a return of 173.9% compared to the index's 4.6% [6].
中自科技(688737):2024年年报及2025年一季报点评:催化剂市场开拓成绩斐然,复材业务重点布局碳纤维PEEK方向
EBSCN· 2025-05-05 14:24
2025 年 5 月 5 日 公司研究 催化剂市场开拓成绩斐然,复材业务重点布局碳纤维 PEEK 方向 ——中自科技(688737.SH)2024 年年报及 2025 年一季报点评 要点 事件:公司发布 2024 年年度报告及 2025 年一季报。公司 2024 全年实现营业 收入 15.65 亿元,同比增长 1.35%;归母净利润为-0.26 亿元。2025 年一季度 营业收入 4.03 亿元,同比增长 7.52%;实现归母净利润 0.08 亿元,同比下降 46.91%。公司研发投入持续加大,2024 年研发投入为 1.10 亿元,同比增长 26.44%。 催化剂业务市场拓展成绩斐然,储能业务高速成长。2024 年内燃机尾气净化催 化剂收入为 14.53 亿元,同比下滑 3.90%;毛利率为 9.30%,同比减少 1.33 个 百分点。其中,公司汽油车尾气净化催化剂产品 2024 年销量首次突破百万套, 新增获得国内大客户多款平台项目定点并首次进入某合资品牌供应商体系。工业 催化剂收入为 1387.86 万元,同比增长 65.73%。2024 年公司成功中标兰州石 化 8 万吨/年丙烯酸及 10 万吨/年丙 ...
安井食品24年报&25Q1点评:稳中求进,静待新品发力
Huaan Securities· 2025-05-05 14:23
稳中求进,静待新品发力 安井食品( [Table_StockNameRptType] 603345) 公司点评 ——安井食品 24 年报&25Q1 点评 [Table_Rank] 投资评级:买入(维持) 报告日期: 2025-05-05 | [Table_BaseData] 收盘价(元) | 76.30 | | --- | --- | | 近 个月最高 / 最 低 12 | 107.89/66.13 | | (元) | | | 总股本(百万股) | 293 | | 流通股本(百万股) | 293 | | 流通股比例(%) | 100.00 | | 总市值(亿元) | 224 | | 流通市值(亿元) | 224 | [公司价格与沪深 Table_Chart] 300 走势比较 -38% -22% -6% 10% 26% 5/24 8/24 11/24 2/25 安井食品 沪深300 [Table_Author] 分析师:邓欣 执业证书号:S0010524010001 邮箱:dengxin@hazq.com 联系人:郑少轩 执业证书号:S0010124040001 邮箱:zhengshaoxuan@hazq.c ...
可孚医疗:聚焦核心品类,结构调整提升盈利能力-20250505
Xinda Securities· 2025-05-05 14:23
相关研究 [Table_OtherReport] 销售毛利率逐季提升,长期成长可期 核心品类同比增 30%+, 盈利能力提升 可期 五大产品线均衡发展, 听力保健成长 可期 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B 座 邮编:100031 [Table_Title] 聚焦核心品类,结构调整提升盈利能力 证券研究报告 公司研究 [Table_ReportType] 公司点评报告 [Table_StockAndRank] 可孚医疗(301087) | 投资评级 | 买入 | | --- | --- | | 上次评级 | 买入 | | 执业编号:S1500523080002 | | | --- | --- | | [Table_Author] 唐爱金 邮 | 医药行业首席分析师 箱:tangaijin@cindasc.com | 曹佳琳 医药行业分析师 执业编号:S1500523080011 邮 箱:caojialin@cindasc.com [Table_ReportDate] 2025 年 05 月 05 日 [Table_S 事件:公 ...
比音勒芬:践行年轻化战略,重塑品牌形象-20250505
Tianfeng Securities· 2025-05-05 14:23
Investment Rating - The investment rating for the company is "Buy" with a target price not specified [5][16] Core Views - The company is implementing a youth-oriented strategy to reshape its brand image, transitioning from being recognized as the "first association brand in golf" to a multi-brand strategy in the apparel sector [3] - The company has reported a revenue of 1.3 billion yuan in Q1 2025, a year-on-year increase of 1%, while the net profit attributable to the parent company was 300 million yuan, down 8% year-on-year [1] - The company plans to distribute a cash dividend of 5 yuan per 10 shares, totaling 290 million yuan, with a payout ratio of 37% [1] Financial Performance Summary - For the year 2024, the company reported a revenue of 4 billion yuan, a 13% increase year-on-year, and a net profit of 800 million yuan, down 14% year-on-year [1] - The company's direct sales revenue for 2024 was 2.6 billion yuan, up 7% year-on-year, with a gross margin of 81% [1] - The franchise revenue for 2024 was 1.1 billion yuan, up 24% year-on-year, with a gross margin of 70% [1] - E-commerce revenue reached 300 million yuan, a 35% increase year-on-year, with a gross margin of 75% [1] Profitability Adjustments - The profit forecast for 2025-2027 has been adjusted, with expected revenues of 4.2 billion, 4.4 billion, and 4.8 billion yuan respectively [4] - The net profit attributable to the parent company is projected to be 820 million, 880 million, and 960 million yuan for 2025-2027 [4] - The earnings per share (EPS) is expected to be 1.4, 1.5, and 1.7 yuan for the same period [4]
信科移动:亏损持续收窄,运营质量改善-20250505
Tianfeng Securities· 2025-05-05 14:23
公司报告 | 年报点评报告 信科移动(688387) 证券研究报告 亏损持续收窄,运营质量改善 24 年受运营商开支资本下滑影响仍亏损,但亏损收窄、经营现金流转正 公司公布 24 年年报及 25 年一季报,24 年实现营业收入 64.91 亿元,同比 减少 17%,归母净利润-2.79 亿元,同比减亏 0.79 亿元,扣非后归母净利 润-4.27 亿元,同比减亏 1.39 亿元。经营现金流净额 7.03 亿元,首次实现 转正,公司运营质量持续改善。亏损主要原因是运营商基站资本开支明显 下滑,市场有效需求不足,公司收入规模同比下降,同时保持较高强度的 研发投入水平,导致 2024 年处于亏损状态。25 年一季度实现营业收 8.15 亿元,同比减少 16%,归母净利润-1.56 亿元,与去年同期的-1.59 亿元基 本持平。 系统设备收入下降,但毛利率提升 24 年系统设备收入 13.92 亿元,同比减少 40%,毛利率提升 3.2 个百分点 至 39.34%。中标中国移动 5G 无线主设备六期集采项目、中国电信 5G 六期 工程,中国联通六期工程实现超框架落地,积极推进 5G-A 试点,5G-A 通 感试验网一 ...